SG10201709555SA - High-concentration monoclonal antibody formulations - Google Patents

High-concentration monoclonal antibody formulations

Info

Publication number
SG10201709555SA
SG10201709555SA SG10201709555SA SG10201709555SA SG10201709555SA SG 10201709555S A SG10201709555S A SG 10201709555SA SG 10201709555S A SG10201709555S A SG 10201709555SA SG 10201709555S A SG10201709555S A SG 10201709555SA SG 10201709555S A SG10201709555S A SG 10201709555SA
Authority
SG
Singapore
Prior art keywords
monoclonal antibody
antibody formulations
concentration monoclonal
concentration
formulations
Prior art date
Application number
SG10201709555SA
Inventor
Nicholas J Armstrong
Mayumi N Bowen
Yuh-Fun Maa
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48471141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201709555S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10201709555SA publication Critical patent/SG10201709555SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
SG10201709555SA 2012-05-18 2013-05-17 High-concentration monoclonal antibody formulations SG10201709555SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261649146P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
SG10201709555SA true SG10201709555SA (en) 2017-12-28

Family

ID=48471141

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407512VA SG11201407512VA (en) 2012-05-18 2013-05-17 High-concentration monoclonal antibody formulations
SG10201709555SA SG10201709555SA (en) 2012-05-18 2013-05-17 High-concentration monoclonal antibody formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201407512VA SG11201407512VA (en) 2012-05-18 2013-05-17 High-concentration monoclonal antibody formulations

Country Status (22)

Country Link
US (4) US20130309226A1 (en)
EP (2) EP2849723B1 (en)
JP (3) JP6254581B2 (en)
KR (2) KR102201607B1 (en)
CN (2) CN108187043A (en)
AU (3) AU2013262611B2 (en)
BR (1) BR112014028600B1 (en)
CA (1) CA2873646C (en)
ES (1) ES2682761T3 (en)
HK (2) HK1207826A1 (en)
HR (1) HRP20181211T1 (en)
IL (3) IL235716B (en)
MX (1) MX355611B (en)
MY (1) MY188825A (en)
NZ (3) NZ737862A (en)
PL (1) PL2849723T3 (en)
RU (2) RU2019142698A (en)
SG (2) SG11201407512VA (en)
SI (1) SI2849723T1 (en)
TR (1) TR201810930T4 (en)
WO (1) WO2013173687A1 (en)
ZA (2) ZA201408651B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6063877B2 (en) 2011-03-10 2017-01-18 ゼリス ファーマシューティカルズ インコーポレイテッド Stable formulation for parenteral injection of peptide drugs
HUE051644T2 (en) 2011-11-18 2021-03-01 Regeneron Pharma Micro-particle containing therapeutic protein coated with biodegradable polymer for medical use
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
MX2016003182A (en) 2013-09-11 2017-03-31 Arsia Therapeutics Inc Liquid protein formulations containing ionic liquids.
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP6738316B2 (en) * 2014-07-17 2020-08-12 ノヴォ ノルディスク アクティーゼルスカブ Site-directed mutagenesis of TREM-1 antibody to reduce viscosity
CA2957399C (en) 2014-08-06 2023-09-26 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
MX2017004306A (en) 2014-10-01 2017-12-20 Eagle Biologics Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents.
RU2699544C2 (en) 2015-01-28 2019-09-06 Пфайзер Инк. Stable aqueous anti-vascular endothelial growth factor (vegf) antibody composition
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US20170056504A1 (en) * 2015-09-02 2017-03-02 Kenneth I. Kohn Method of extending half-life of crystaline antibodies
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
EP4059492B1 (en) 2015-12-16 2024-04-17 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
CA3019482A1 (en) 2016-03-31 2017-10-05 Vhsquared Limited Compositions
MA46466A (en) 2016-10-06 2019-08-14 Amgen Inc PHARMACEUTICAL FORMULATIONS OF REDUCED VISCOSITY PROTEINS
WO2018078186A1 (en) 2016-10-31 2018-05-03 Vectura Limited Inhalable powder composition comprising il-13 antibody
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR20240036128A (en) 2017-06-02 2024-03-19 엑스에리스 파머수티클스, 인크. Precipitation resistant small molecule drug formulations
EP3849615A1 (en) 2018-09-12 2021-07-21 Silverback Therapeutics, Inc. Compositions for the treatment of disease with immune stimulatory conjugates
WO2020071876A1 (en) * 2018-10-04 2020-04-09 삼성바이오에피스 주식회사 High concentration trastuzumab with reduced viscosity or antigen-binding fragment stabilizing agent thereof
JP2022532965A (en) * 2018-11-21 2022-07-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド High-concentration protein preparation
SG11202107901QA (en) 2019-02-05 2021-08-30 Lindy Biosciences Inc Isolated cell culture components and methods for isolating the same from liquid cell culture medium
BR112021015034A2 (en) 2019-02-18 2021-10-05 Eli Lilly And Company THERAPEUTIC ANTIBODY FORMULATION
MX2021010689A (en) * 2019-03-06 2021-10-01 Zoetis Services Llc Ready-to-use injectable formulations.
SG11202110546UA (en) * 2019-04-11 2021-10-28 R P Scherer Technologies Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
KR20220035908A (en) 2019-06-19 2022-03-22 실버백 테라퓨틱스, 인크. Anti-Mesothelin Antibodies and Immunoconjugates Thereof
CN114466864A (en) 2019-06-21 2022-05-10 索瑞索制药公司 Polypeptides
MX2021015763A (en) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polypeptides.
JP2023503287A (en) * 2019-11-27 2023-01-27 ノバリック ゲーエムベーハー Suspension formulation containing protein particles suspended in non-aqueous solvent
CN113082203B (en) * 2020-01-09 2023-10-20 鲁南制药集团股份有限公司 Liquid preparation of immunosuppressant monoclonal antibody
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
AU2021300362A1 (en) 2020-07-01 2023-02-23 ARS Pharmaceuticals, Inc. Anti-ASGR1 antibody conjugates and uses thereof
KR102375269B1 (en) * 2021-01-27 2022-03-17 한미약품 주식회사 Protein aqueous formulations and method for manufacturing thereof
WO2023013929A1 (en) 2021-08-05 2023-02-09 주식회사 엘지에너지솔루션 Electrode assembly, battery, and battery pack and vehicle comprising same
WO2023013933A1 (en) 2021-08-05 2023-02-09 주식회사 엘지에너지솔루션 Electrode assembly, cylindrical battery cell, and battery pack and vehicle including same
CA3231500A1 (en) * 2021-09-09 2023-03-16 Xeris Pharmaceuticals, Inc. Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE947335C (en) 1954-10-19 1956-08-16 Schering Ag Process for the production of stable oily solutions from Oestron
GB1225979A (en) 1967-03-23 1971-03-24
US3639587A (en) 1969-11-07 1972-02-01 Eastman Kodak Co Medicinal compositions for administration to animals and process for administering same
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
DE2949849A1 (en) 1979-12-12 1981-06-19 A. Nattermann & Cie GmbH, 5000 Köln Phosphatidyl-choline i.e. lecithin solns. - for oral admin. e.g. in soft gelatin capsules using lactic acid ester(s) pref. ethyl lactate as solvent
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
WO1989012463A1 (en) 1988-06-21 1989-12-28 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
DE69233716T2 (en) 1991-08-14 2008-10-30 Genentech Inc., San Francisco Immunoglobulin variants for specific Fc epsilon receptors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69333082T2 (en) 1992-02-11 2004-05-06 Cell Genesys, Inc., Foster City OBTAINING HOMOZYGOTEM BY TARGETED GENETIC EVENTS
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE161192T1 (en) 1992-08-21 1998-01-15 Genentech Inc METHOD FOR TREATING A DISORDER MEDIATED BY LFA-1
CA2176811C (en) 1993-12-10 2008-01-29 David Tai Wai Fei Methods for diagnosis of allergy and screening of anti-allergy therapeutics
MX9602818A (en) 1994-01-18 1997-06-28 Genentech Inc A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS.
WO1995023865A1 (en) 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
WO1997004801A1 (en) * 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE222774T1 (en) 1996-01-23 2002-09-15 Genentech Inc ANTIBODIES TO CD 18 FOR USE AGAINST BRAIN STROKE
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1516629B1 (en) 1996-11-27 2013-04-03 Genentech, Inc. Humanized anti CD-11a antibodies
EP0981618B2 (en) 1997-05-15 2011-08-24 Genentech, Inc. Anti-apo-2 antibody
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
IL149116A0 (en) 1999-10-29 2002-11-10 Genentech Inc Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
AU2001277781A1 (en) 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
AU1344102A (en) 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
CN1555411A (en) 2001-08-03 2004-12-15 ���迨�����＼���ɷݹ�˾ Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003217415B2 (en) 2002-02-14 2009-01-08 William J Rutter Chimeric molecules for cleavage in a treated host
CN1638798A (en) 2002-02-14 2005-07-13 中外制药株式会社 Antibody-containing solution pharmaceuticals
JP4498746B2 (en) 2002-02-14 2010-07-07 イミューノメディクス、インコーポレイテッド Anti-CD20 antibody and fusion protein thereof and method of use
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
KR100944575B1 (en) 2002-10-17 2010-02-25 젠맵 에이/에스 Human monoclonal antibodies against cd20
AU2004209638B2 (en) 2003-02-01 2011-02-03 Tanox, Inc. High affinity anti-human IgE antibodies
JP4869064B2 (en) * 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド High concentration antibody and protein preparation
US20070032465A1 (en) 2003-05-29 2007-02-08 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha
RS20181002A1 (en) * 2003-05-30 2018-12-31 Genentech Inc Treatment with anti-vegf antibodies
PL1692182T3 (en) 2003-11-05 2010-09-30 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
CA2566075A1 (en) * 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
EP1786400B1 (en) 2004-08-12 2009-03-11 Quest Pharmaceutical Services Pharmaceutical compositions for controlled release delivery of biologically active compounds
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060216242A1 (en) 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR101429774B1 (en) * 2005-05-09 2014-10-02 바이오스피어 메디칼 에스.에이. Compositions and methods using microspheres and non-ionic contrast agents
AU2006330858A1 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antibody-containing stabilizing preparation
WO2007092772A2 (en) * 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
PL2046833T3 (en) 2006-07-14 2014-01-31 Ac Immune Sa Humanized antibody against amyloid beta
US20090022727A1 (en) * 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
CN101679528B (en) 2007-03-22 2013-11-06 健泰科生物技术公司 Apoptotic anti-IGE antibodies
US7611705B2 (en) * 2007-06-15 2009-11-03 National Cheng Kung University Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
CN104188911A (en) 2008-01-15 2014-12-10 Abbvie德国有限责任两合公司 Powdered protein compositions and methods of making same
WO2010056657A2 (en) * 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
ES2693700T3 (en) * 2008-11-19 2018-12-13 Merial, Inc. Formulations comprising ceftiofur and benzyl alcohol
TWI461211B (en) 2009-03-20 2014-11-21 Genentech Inc Anti-her antibodies
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
CA2776474C (en) * 2009-10-02 2021-01-12 Foamix Ltd. Topical tetracycline compositions
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US20130202693A1 (en) * 2010-06-02 2013-08-08 Astellas Deutschland Gmbh Oral Dosage Forms of Bendamustine

Also Published As

Publication number Publication date
JP2018090581A (en) 2018-06-14
KR102201607B1 (en) 2021-01-12
US20130309226A1 (en) 2013-11-21
AU2020204588A1 (en) 2020-07-30
EP2849723A1 (en) 2015-03-25
NZ737862A (en) 2020-01-31
CN104427974A (en) 2015-03-18
MY188825A (en) 2022-01-06
PL2849723T3 (en) 2018-10-31
RU2014151359A (en) 2016-07-10
AU2018203876B2 (en) 2020-04-09
CN104427974B (en) 2018-03-23
IL235716A0 (en) 2015-01-29
ZA202109290B (en) 2023-07-26
HRP20181211T1 (en) 2018-10-05
JP2020059716A (en) 2020-04-16
AU2013262611A1 (en) 2015-01-15
JP6254581B2 (en) 2017-12-27
JP7015156B2 (en) 2022-02-02
ES2682761T3 (en) 2018-09-21
WO2013173687A1 (en) 2013-11-21
HK1207826A1 (en) 2016-02-12
AU2013262611B2 (en) 2018-03-01
KR102326359B1 (en) 2021-11-12
RU2019142698A (en) 2020-05-27
EP2849723B1 (en) 2018-05-02
IL268280B (en) 2021-05-31
KR20150009593A (en) 2015-01-26
HK1257554A1 (en) 2019-10-25
US20200087415A1 (en) 2020-03-19
CA2873646A1 (en) 2013-11-21
SI2849723T1 (en) 2018-09-28
KR20210103388A (en) 2021-08-23
AU2018203876A1 (en) 2018-06-21
JP2015520164A (en) 2015-07-16
NZ725654A (en) 2018-04-27
RU2711089C2 (en) 2020-01-15
MX2014013868A (en) 2015-05-15
BR112014028600A2 (en) 2017-08-01
IL282805A (en) 2021-06-30
US20210292435A1 (en) 2021-09-23
TR201810930T4 (en) 2018-08-27
SG11201407512VA (en) 2014-12-30
BR112014028600A8 (en) 2021-09-14
NZ701915A (en) 2016-11-25
ZA201408651B (en) 2022-09-28
CA2873646C (en) 2022-04-26
BR112014028600B1 (en) 2022-11-22
US20160176986A1 (en) 2016-06-23
EP3427721A1 (en) 2019-01-16
MX355611B (en) 2018-04-25
IL268280A (en) 2019-09-26
IL235716B (en) 2019-08-29
CN108187043A (en) 2018-06-22

Similar Documents

Publication Publication Date Title
ZA202109290B (en) High-concentration monoclonal antibody formulations
IL276234B (en) Antibody formulations
HRP20181646T1 (en) Pyrrolobenzodiazepine - anti-psma antibody conjugates
IL235807A0 (en) Immunoconjugates comprising anti-cd79b antibodies
IL235989A0 (en) Immunoconjugates comprising anti-cd79b antibodies
ZA201502267B (en) Pyrrolobenzodiazepine-anti-her2 antibody conjugates
LT3117837T (en) Antibody formulations
RS56520B1 (en) Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
EP2826790A4 (en) Gremlin-1 antibody
EP2811018A4 (en) ANTI-sAPPß ANTIBODY